NICE does not recommend Roche's ocrelizumab for primary progressive MS
The U.K.'s NICE said in an appraisal consultation it does not recommend the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis (MS) with imaging features characteristic of inflammatory activity in adults. NICE concluded ocrelizumab compared with best supportive care alone is not cost-effective at the patient access scheme price or at the lower proposed commercial arrangement price.
The incremental cost-effectiveness ratio at the patient access scheme price is £78,316 ($103,733) per quality-adjusted life year (QALY) gained in the deterministic model and £84,249 ($111,592) per QALY gained in the probabilistic model...
BCIQ Company Profiles
BCIQ Target Profiles